These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20624784)

  • 1. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.
    von Minckwitz G; Eidtmann H; Loibl S; Blohmer JU; Costa SD; Fasching PA; Kreienberg R; Hilfrich J; Gerber B; Hanusch C; Fehm T; Strumberg D; Solbach C; Nekljudova V; Untch M;
    Ann Oncol; 2011 Feb; 22(2):301-6. PubMed ID: 20624784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
    von Minckwitz G; Loibl S; Untch M; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Gerber B; ; Gnauert K; Heinrich B; Prätz T; Groh U; Tanzer H; Villena C; Tulusan A; Liedtke B; Blohmer JU; Kittel K; Mau C; Potenberg J; Schilling J; Just M; Weiss E; Bückner U; Wolfgarten M; Lorenz R; Doering G; Feidicker S; Krabisch P; Deichert U; Augustin D; Kunz G; Kast K; von Minckwitz G; Nestle-Krämling C; Rezai M; Höß C; Terhaag J; Fasching P; Staib P; Aktas B; Kühn T; Khandan F; Möbus V; Solbach C; Tesch H; Stickeler E; Heinrich G; Wagner H; Abdallah A; Dewitz T; Emons G; Belau A; Rethwisch V; Lantzsch T; Thomssen C; Mattner U; Nugent A; Müller V; Noesselt T; Holms F; Müller T; Deuker JU; Schrader I; Strumberg D; Uleer C; Solomayer E; Runnebaum I; Link H; Tomé O; Ulmer HU; Conrad B; Feisel-Schwickardi G; Eidtmann H; Schumacher C; Steinmetz T; Bauerfeind I; Kremers S; Langanke D; Kullmer U; Ober A; Fischer D; Kohls A; Weikel W; Bischoff J; Freese K; Schmidt M; Wiest W; Sütterlin M; Dietrich M; Grießhammer M; Burgmann DM; Hanusch C; Rack B; Salat C; Sattler D; Tio J; von Abel E; Christensen B; Burkamp U; Köhne CH; Meinerz W; Graßhoff ST; Decker T; Overkamp F; Thalmann I; Sallmann A; Beck T; Reimer T; Bartzke G; Deryal M; Weigel M; Huober J; Weder P; Steffens CC; Lemster S; Stefek A; Ruhland F; Hofmann M; Schuster J; Simon W; Kronawitter U; Clemens M; Fehm T; Janni W; Latos K; Bauer W; Roßmann A; Bauer L; Lampe D; Heyl V; Hoffmann G; Lorenz-Salehi F; Hackmann J; Schlag R
    Ann Oncol; 2014 Dec; 25(12):2363-2372. PubMed ID: 25223482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
    Huober J; Fasching PA; Hanusch C; Rezai M; Eidtmann H; Kittel K; Hilfrich J; Schwedler K; Blohmer JU; Tesch H; Gerber B; Höß C; Kümmel S; Mau C; Jackisch C; Khandan F; Costa SD; Krabisch P; Loibl S; Nekljudova V; Untch M; Minckwitz Gv
    Eur J Cancer; 2013 Jul; 49(10):2284-93. PubMed ID: 23541564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
    Untch M; Loibl S; Bischoff J; Eidtmann H; Kaufmann M; Blohmer JU; Hilfrich J; Strumberg D; Fasching PA; Kreienberg R; Tesch H; Hanusch C; Gerber B; Rezai M; Jackisch C; Huober J; Kühn T; Nekljudova V; von Minckwitz G; ;
    Lancet Oncol; 2012 Feb; 13(2):135-44. PubMed ID: 22257523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
    Gerber B; Loibl S; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Nekljudova V; Untch M; von Minckwitz G;
    Ann Oncol; 2013 Dec; 24(12):2978-84. PubMed ID: 24136883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
    Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
    J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.
    Crown J; Kennedy MJ; Tresca P; Marty M; Espie M; Burris HA; DeSilvio M; Lau MR; Kothari D; Koch KM; Diéras V
    Ann Oncol; 2013 Aug; 24(8):2005-11. PubMed ID: 23878115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
    von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
    J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
    N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined chemotherapy with molecular-targeted agent for breast cancer].
    Ito Y; Miura H
    Gan To Kagaku Ryoho; 2008 May; 35(5):731-6. PubMed ID: 18487908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
    Guarneri V; Frassoldati A; Bottini A; Cagossi K; Bisagni G; Sarti S; Ravaioli A; Cavanna L; Giardina G; Musolino A; Untch M; Orlando L; Artioli F; Boni C; Generali DG; Serra P; Bagnalasta M; Marini L; Piacentini F; D'Amico R; Conte P
    J Clin Oncol; 2012 Jun; 30(16):1989-95. PubMed ID: 22493419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.
    Alba E; Albanell J; de la Haba J; Barnadas A; Calvo L; Sánchez-Rovira P; Ramos M; Rojo F; Burgués O; Carrasco E; Caballero R; Porras I; Tibau A; Cámara MC; Lluch A
    Br J Cancer; 2014 Mar; 110(5):1139-47. PubMed ID: 24457911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
    Gadgeel SM; Lew DL; Synold TW; LoRusso P; Chung V; Christensen SD; Smith DC; Kingsbury L; Hoering A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1089-96. PubMed ID: 24057042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.